{"id":"reducing-dose-of-lopinavir","safety":{"commonSideEffects":[{"rate":"15–30%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Nausea"},{"rate":"5–15%","effect":"Abdominal pain"},{"rate":"20–40%","effect":"Lipid abnormalities (elevated triglycerides and cholesterol)"},{"rate":"2–5%","effect":"Hepatotoxicity"},{"rate":"5–10%","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir binds to the active site of HIV protease, a viral enzyme essential for processing precursor polyproteins into mature, functional viral proteins. By preventing this proteolytic cleavage, lopinavir causes the production of immature, non-infectious viral particles. This mechanism is the basis for its antiretroviral activity, and dose reduction is typically employed to minimize toxicity while maintaining therapeutic efficacy, often in combination with other antiretroviral agents.","oneSentence":"Lopinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and thereby inhibiting HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:32.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination with ritonavir and other antiretroviral agents)"}]},"trialDetails":[{"nctId":"NCT05850728","phase":"PHASE1","title":"First in Human Study of TLC-ART 101 (ACTU 2001)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2023-04-01","conditions":"Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy","enrollment":12},{"nctId":"NCT04667780","phase":"PHASE3","title":"Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19","status":"COMPLETED","sponsor":"Ayub Teaching Hospital","startDate":"2020-12-01","conditions":"COVID-19","enrollment":102},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT04403100","phase":"PHASE3","title":"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: \"The Hope Coalition - 1\"","status":"UNKNOWN","sponsor":"Cardresearch","startDate":"2020-06-03","conditions":"COVID-19, Coronavirus Infection, Virus Disease","enrollment":1968},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT04350320","phase":"PHASE3","title":"Trial to Study the Benefit of Colchicine in Patients With COVID-19","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2020-04-30","conditions":"COVID19","enrollment":102},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01159275","phase":"PHASE1, PHASE2","title":"Lopinavir (LPV) Dose Reduction","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-07","conditions":"HIV-1 Infections","enrollment":20},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT00836212","phase":"PHASE4","title":"Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2008-03","conditions":"Human Immunodeficiency Virus, HIV Infections","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Reducing dose of Lopinavir","genericName":"Reducing dose of Lopinavir","companyName":"University Hospital, Geneva","companyId":"university-hospital-geneva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and thereby inhibiting HIV replication. Used for HIV-1 infection (in combination with ritonavir and other antiretroviral agents).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}